Volume 21, Number 7—July 2015
CME ACTIVITY - Research
Parechovirus Genotype 3 Outbreak among Infants, New South Wales, Australia, 2013–2014
Table 2
HPeV testing of specimens from patients from New South Wales, received at the VIDRL, Melbourne, Victoria, Australia, November 1, 2013–February 28, 2014, by specimen type*
Sample and result |
Specimens, no. (%) |
Patients, no. (%) |
Total | 420 (100) | 308 (100) |
CSF | ||
Total samples tested | 168 (40) | 161 (52) |
HPeV+ (mean Ct 31.6)† | 123 (73) | 116 (72) |
PCR+ for HPeV and EV | 1 (1) | 1 (1) |
Stool | ||
Total samples tested | 156 (37) | 147 (48) |
HPeV+ (mean Ct 27.2) | 114 (73) | 106 (72) |
PCR+ for HPeV and EV | 2 (1) | 2 (1) |
Other | ||
Total samples tested | 96 (23) | 8 (28) |
HPeV+ | 52 (54) | 45 (52) |
PCR+ for HPeV and EV | 1 (1) | 1 (1) |
Sequenced: HPeV3 | 41 (14) | 41 (21) |
*CSF, cerebrospinal fluid; Ct, cycle threshold; EV, enterovirus; HPeV, human parechovirus; VIDRL, Victorian Infectious Disease Reference Laboratory: +, positive.
†At VIDRL, PCRs are run for 45 cycles, so any Ct value greater than 45 is considered negative.
1Current affiliation: Independent consultant, Freshwater, New South Wales, Australia